Spinal transforaminal neurostimulation with FAST and MultiWave for refractory chronic neuropathic pain
Official title: Prospective, Longitudinal, Single-arm Interventional Study Evaluating the Efficacy of Spinal Transforaminal NeuroStimulation (STNS) With FAST and MULTIWAVE Stimulation in Patients With Refractory Chronic Neuropathic Pain
Run by Poitiers University Hospital · NCT07154056 · Data updated 2026-11-12
This trial will test whether spinal transforaminal neurostimulation using FAST and MultiWave waveforms can reduce long-standing neuropathic peripheral pain in adults whose pain has not responded to other treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 17 (estimated) |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 1 site (Poitiers, France) |
| Status | Recruiting |
| Started | February 10, 2026 |
| Main results expected | February 10, 2027 |
| Study ends | October 10, 2027 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07154056 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with non-cancer neuropathic peripheral pain for at least 6 months, a VAS of 5 or higher, stable pain and medication for 30 days, eligibility for spinal transforaminal neurostimulation per French guidance, and coverage by French national health insurance are ideal candidates.
✕Probably not a fit
People with coagulation disorders, prior spinal cord/subcutaneous/peripheral nerve stimulation or intrathecal drug delivery systems, cancer-related pain, or those who are not candidates for implantation are unlikely to be helped or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study implants transforaminal leads and an implantable pulse generator (IPG) to deliver FAST and MultiWave stimulation patterns aimed at relieving chronic neuropathic peripheral pain. Eligible adults (18–80 years) must have at least 6 months of neuropathic pain, a baseline VAS ≥5, stable pain and medication regimens, and pass a multidisciplinary pre-implant assessment per French National Authority for Health guidance. After implantation, patients are followed to measure changes in pain intensity, device energy consumption, and safety/tolerability. The protocol emphasizes low-energy settings and selection criteria to minimize procedural risk.
Why it matters
Potential benefit: If successful, this approach could give people with refractory neuropathic pain better pain relief with lower energy use and a lower procedural risk profile compared with some existing options.
How similar studies have gone: Related neuromodulation methods such as spinal cord stimulation and peripheral nerve stimulation have demonstrated pain relief in neuropathic pain, but STNS with FAST/MultiWave is relatively novel with limited published outcome data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has ≥ 18 years and ≤ 80 years * Subject has a global Visual Analogic Scale ≥ 5 * Subject has non-cancer pain with a significant neuropathic component for at least 6 months. * Subject has stable pain for at least 30 days * Pain medication(s) dosage(s) is/are stable for at least 30 days * Subject is eligible for Spinal Transforaminal NeuroStimulation after a pre-implantation assessment by a multidisciplinary team, as described by the French National Authority for Health (Haute Autorité de Santé) * Subject understands and accepts the constraints of the study and is able to use the equipment. * Patient is covered by French national health insurance. * Subject has given written consent to the study after having received clear and complete information. Non-inclusion Criteria: * Subject has a coagulation disorder * Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system * Subject has had corticosteroid therapy within the past 30 days * Subject has had radiofrequency therapy within the past 3 months * Subject has been diagnosed with cancer in the past 2 years * Subject has had a spinal surgery within the past 6 months * Simultaneous participation to any interventional study on health product or any study able to interfere with the current study endpoints. * Subject has at least one of brain MRI contraindications such as : intracranial clips /Vascular clips/Pace maker/Heart battery, Defibrillator, Implanted Holter (REVEAL type), Neuro-stimulator not compatible with 1.5 T MRI/Stents/ Coils/Cardiac valves (heart)/ Shunt valve/Implanted injection pump/Cochlear implants/Implantable chamber (PAC)/Intracorporeal metal shards/ metallic foreign bodies, the location and the presence of implanted neurostimulation components that are not listed as MRI Conditional, cardiac implantable electronic device, metallic intraocular foreign bodies, cochlear implants, drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing. * Subjects requiring closer protection, i.e. minors, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients in an emergency setting * Pregnant or breastfeeding women, women at age to procreate and not using effective contraception.
Where it's running
-
Poitiers University Hospital
Poitiers, France, France Recruiting
Study contacts
- Study coordinator: Philippe Rigoard, MD, PhD
- Email: philippe.rigoard@chu-poitiers.fr
- Phone: +33549443548
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
aiTBS and rTMS for Chronic Neuropathic Pain: see if brain stimulation helps
This study tests whether two brain stimulation methods (aiTBS and high-frequency rTMS) can reduce pain in adults with chronic neuropathic pain, compared with sham stimulation.
-
MDMA for severe chronic neuropathic pain
This will try a single oral dose of MDMA combined with psychotherapy to see if it reduces pain and improves function in adults with moderate-to-severe chronic neuropathic pain that hasn't responded to standard medications.
-
rTMS over the motor cortex for cancer-related neuropathic pain
This trial will try high-frequency rTMS over the primary motor cortex to relieve chronic neuropathic pain in adults with cancer who have not responded to standard drug treatments.
-
Peripheral nerve stimulation to relieve chronic neuropathic pain in the low back, pelvis, and legs
This trial tests whether adding peripheral nerve stimulation (using Nalu or SPRINT devices) to usual medical care helps adults with chronic neuropathic pain in the lower back, pelvis, or legs reduce pain and have better treatment responses.
-
Using psilocybin to help manage chronic neuropathic pain
This study is testing if psilocybin can help adults with chronic nerve pain find relief when other medications haven't worked.
-
Using low dose naltrexone to treat pain in HIV patients
This study is testing whether low dose naltrexone can help relieve chronic pain in people living with HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.